The Food and Drug Administration plans to convene an advisory committee in February 2005 to review cardiovascular safety of all COX-2 inhibitors. "We look forward to a scientific and reasoned evaluation in this appropriate setting," Dr. Feczko said.

Additional Information on Bextra

Bextra is contraindicated in patients who have demonstrated allergic-type reactions to sulfonamides; in patients with known hypersensitivity to valdecoxib; and in patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or NSAIDs because severe, rarely fatal, anaphylactic-like reactions to NSAIDS are possible in such patients. In rare cases, serious skin reactions can occur. Fatalities due to Stevens- Johnson syndrome and toxic epidermal necrolysis have been reported. If an allergic reaction is suspected or if there are other severe or unusual symptoms while taking Bextra, a patient should call his or her doctor or other healthcare professional immediately.

DISCLOSURE NOTICE: The information contained in this document is as of November 10, 2004. Pfizer assumes no obligation to update any forward-looking statements contained in this document as a result of new information or future events or developments.

This document contains forward-looking information. A list and description of risks and uncertainties relating to matters discussed in this document can be found in Company's Annual Report on Form 10-K for fiscal year ended December 31, 2003, and in its periodic reports on Forms 10-Q and 8-K.

(1) White WB, et al. "Effects of Cyclooxygenase-2 Specific Inhibitor Valdecoxib Versus Nonsteroidal Antiinflammatory Agents and Placebo on Cardiovascular Thrombotic Events in Patients with Arthritis." American Journal of Therapeutics. 2004; 11: 244-250. Number 4.